Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217 · View on ClinicalTrials.gov ↗
Study Summary
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.
Conditions Studied
Interventions
- COMBINATION_PRODUCT AP01
Study Locations (20)
New York
- Icahn School of Medicine at Mount Sinai — New York
- Columbia University — New York
North Carolina
- Piedmont HealthCare, PA — Statesville
- Southeastern Research Center — Winston-Salem
Ohio
- University of Cincinnati — Cincinnati
- The University of Kansas Medical Center — Kansas
Pennsylvania
- Thomas Jefferson University — Philadelphia
- Temple University Hospital — Philadelphia
South Carolina
- Lowcountry Lung and Critical Care, PA — Charleston
- Medical University of South Carolina — Charleston
Colorado
- University of Colorado, Anschutz Medical Campus — Aurora
Florida
- Renstar Medical Research — Ocala
Georgia
- Piedmont Healthcare, Inc. — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06951217
The ClinicalTrials.gov registry entry for NCT06951217 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avalyn Pharma, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 1 intervention — of which AP01 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06951217 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, North Carolina, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06951217 about?
NCT06951217 is a clinical study titled "An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)". This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE...
What is the current status of trial NCT06951217?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2025-04-17. Estimated completion is 2031-12-31.
What conditions does trial NCT06951217 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06951217?
The interventions under investigation include: AP01 (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06951217?
This trial is sponsored by Avalyn Pharma, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06951217 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.